BIOLASE TO REPORT SECOND QUARTER 2023 RESULTS ON AUGUST 10, 2023

Rhea-AI Summary

BIOLASE, Inc. (NASDAQ: BIOL) to release second quarter 2023 financial and operating results on August 10, 2023, followed by a conference call and webcast to discuss the results and corporate developments. Access the live call by dialing 888-506-0062 (U.S.) or +1 973-528-0011 (International) with access code: 679201.

LAKE FOREST, Calif., Aug. 2, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release second quarter 2023 financial and operating results on Thursday, August 10, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.

To access the live call, dial 888-506-0062 (U.S.) or +1 973-528-0011 (International) and provide the following access code: 679201.

A live and archived webcast of the conference call will be accessible on the BIOLASE Investor Relations Page. In addition, a phone replay will be available approximately two hours following the end of the call, and it will remain available for one week. To access the call replay, dial 877-481-4010 or +1 919-882-2331 (International) and enter replay passcode 48764.

About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 266 actively patented and 25 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2022, BIOLASE has sold over 45,500 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus^®, Waterlase Express^™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE^®, Waterlase^® and Waterlase iPlus^® are registered trademarks of BIOLASE, Inc.

Contacts:
EVC Group, Inc.
Michael Polyviou/Todd Kehrli
(732) 232-6914
mpolyviou@evcgroup.com; tkehrli@evcgroup.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-to-report-second-quarter-2023-results-on-august-10-2023-301892019.html

SOURCE BIOLASE, Inc.

FAQ

What is the date of BIOLASE, Inc.'s second quarter 2023 financial and operating results release?

BIOLASE, Inc. (NASDAQ: BIOL) will release its second quarter 2023 financial and operating results on August 10, 2023.

How can I access the live call and webcast to discuss the results and corporate developments?

To access the live call, dial 888-506-0062 (U.S.) or +1 973-528-0011 (International) with access code: 679201. A live and archived webcast of the conference call will be accessible on the BIOLASE Investor Relations Page.

Will there be a phone replay available for the conference call?

Yes, a phone replay will be available approximately two hours following the end of the call, and it will remain available for one week. To access the call replay, dial 877-481-4010 or +1 919-882-2331 (International) and enter replay passcode 48764.